United Therapeutics Co. (NASDAQ:UTHR) Shares Purchased by Renaissance Technologies LLC

Renaissance Technologies LLC raised its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 1.1% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 2,174,692 shares of the biotechnology company’s stock after acquiring an additional 22,978 shares during the quarter. United Therapeutics makes up about 1.2% of Renaissance Technologies LLC’s portfolio, making the stock its 5th largest holding. Renaissance Technologies LLC owned about 4.89% of United Therapeutics worth $692,748,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. ClariVest Asset Management LLC increased its position in shares of United Therapeutics by 120.0% during the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after buying an additional 42 shares during the period. V Square Quantitative Management LLC acquired a new stake in shares of United Therapeutics during the second quarter worth $30,000. Rise Advisors LLC acquired a new stake in shares of United Therapeutics during the first quarter worth $32,000. Innealta Capital LLC acquired a new stake in shares of United Therapeutics during the second quarter worth $33,000. Finally, Benjamin F. Edwards & Company Inc. increased its position in shares of United Therapeutics by 63.6% during the first quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock worth $69,000 after buying an additional 117 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at United Therapeutics

In related news, CFO James Edgemond sold 7,802 shares of the firm’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $345.41, for a total transaction of $2,694,888.82. Following the transaction, the chief financial officer now directly owns 3,210 shares of the company’s stock, valued at $1,108,766.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, COO Michael Benkowitz sold 25,000 shares of the firm’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $323.38, for a total transaction of $8,084,500.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares in the company, valued at $833,350.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO James Edgemond sold 7,802 shares of the firm’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $345.41, for a total transaction of $2,694,888.82. Following the sale, the chief financial officer now owns 3,210 shares of the company’s stock, valued at approximately $1,108,766.10. The disclosure for this sale can be found here. Insiders have sold 114,522 shares of company stock valued at $37,671,474 over the last ninety days. Corporate insiders own 12.50% of the company’s stock.

United Therapeutics Stock Down 0.6 %

United Therapeutics stock opened at $339.12 on Monday. The company has a current ratio of 4.35, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02. The firm’s fifty day moving average price is $336.73 and its two-hundred day moving average price is $287.95. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $366.08. The firm has a market capitalization of $15.09 billion, a price-to-earnings ratio of 16.03, a price-to-earnings-growth ratio of 1.23 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The firm had revenue of $714.90 million for the quarter, compared to the consensus estimate of $691.87 million. During the same period in the previous year, the business earned $5.24 earnings per share. The firm’s revenue for the quarter was up 19.8% on a year-over-year basis. On average, equities research analysts predict that United Therapeutics Co. will post 24.86 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently issued reports on UTHR shares. TD Cowen increased their target price on shares of United Therapeutics from $270.00 to $350.00 and gave the stock a “buy” rating in a research note on Thursday, July 11th. Wells Fargo & Company increased their target price on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 20th. Morgan Stanley lowered shares of United Therapeutics from an “overweight” rating to an “equal weight” rating and increased their target price for the stock from $310.00 to $321.00 in a research note on Thursday, July 11th. UBS Group increased their target price on shares of United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a research note on Monday, July 8th. Finally, Bank of America cut their target price on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a research note on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, three have given a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and an average price target of $350.36.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.